Lyka Labs reports improved set of numbers in Q1FY22
The company has been consistently reducing debt
The company has been consistently reducing debt
The data should be submitted by August 12th 2021
Deal for 100 million doses with additional 100 million through 2023
Innovative solutions and a deep understanding of the market makes this a unique combination
Total income grew in the quarter
EPS climbs to Rs 9.25 for the quarter
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
AstraZeneca, Sinopharm and Moderna were part of the study
It is part of the company’s pain/analgesics portfolio of OTC products
Subscribe To Our Newsletter & Stay Updated